Form 4: Inari Medical CFO Mitch Hill Executes Stock Option, Sells Shares Under 10b5-1 Plan
SEC Form 4
Inari Medical's CFO, Mitch C. Hill, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On July 12, 2024, Mitch C. Hill, the Chief Financial Officer of Inari Medical, Inc., exercised stock options to acquire 5,000 shares of common stock at a price of $0.457 per share.
- Simultaneously, Hill sold 3,035 shares at a weighted average price of $53.72 and 1,965 shares at a weighted average price of $54.31.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 9, 2023.
- Following these transactions, Hill directly owns 179,227 shares of Inari Medical common stock and indirectly owns 1,600 shares through his spouse.
- He also holds options to purchase 66,477 shares.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to utilize 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The impact on the stock is usually minimal unless the transactions are unusually large or frequent.
Comparison to Industry Standards
- Comparing this to similar transactions by CFOs at comparable medical device companies, the size of the sale is not particularly large or small.
- Many CFOs use 10b5-1 plans to manage their equity compensation.
- For example, the CFO of Penumbra, another medical device company, regularly files similar Form 4s for stock sales under a 10b5-1 plan.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- However, the impact is likely to be minimal given the relatively small number of shares involved and the pre-planned nature of the sales.
Key Dates
| Date | Description |
|---|---|
| April 30, 2020 | Options vested with respect to 25% of the shares. |
| November 9, 2023 | Date the reporting person adopted the Rule 10b5-1 trading plan. |
| July 12, 2024 | Date of the reported transactions (option exercise and stock sales). |
| April 23, 2029 | Expiration date of the stock options. |
| July 16, 2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.